Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 30 Technology Dr WARREN NJ 07059-5166 |
Tel: | N/A |
Website: | https://aquestive.com |
IR: | See website |
Key People | ||
Daniel Barber President, Chief Executive Officer, Director | A. Ernest Toth Chief Financial Officer, Senior Vice President | Lori J. Braender Chief Compliance Officer, Senior Vice President, General Counsel and Corporate Secretary |
Peter E. Boyd Senior Vice President - Information Technology, Human Resources and Communications | Cassie Jung Senior Vice President - Operations | Kenneth W. Marshall Senior Vice President, Chief Commercial Officer |
Stephen Wargacki Senior Vice President - Research and Development | A. Mark Schobel Chief Innovation and Technology Officer | Carl Kraus Chief Medical Officer |
Business Overview |
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company's Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate. |
Financial Overview |
For the three months ended 31 March 2024, Aquestive Therapeutics Inc revenues increased 8% to $12.1M. Net loss totaled $12.8M vs. income of $8.1M. Revenues reflect United States segment increase of 28% to $10.4M. Net loss reflects Interest income and other income, net decrease of 98% to $329K (income), Research and development - Balancing increase of 66% to $5.8M (expense). |